SGN-B6A:一种新的韦多丁抗体-药物结合物,用于整合Beta-6用于多种癌症的指示
Robert P Lyon1, Mechthild Jonas1, Christopher Frantz1
1Seagen Inc., Bothell, Washington.
Molecular cancer therapeutics
|August 24, 2023
概括
SGN-B6A是一种针对整合蛋白β-6的抗体-药物结合体,显示出对治疗固体瘤的前景. 临床前研究表明其有效性和可接受的安全性,导致正在进行的I期临床试验.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 集成蛋白β-6 (ITGB6) 在许多固体瘤中过度表达,作为负预后指标.
- 阿尔法-v/β-6整合素是关键的粘附受体,与癌症进展有关.
研究的目的:
- 开发和评估SGN-B6A,一种针对ITGB6的抗体药物联合体 (ADC),用于癌症治疗.
- 评估SGN-B6A的临床前安全性和疗效,提供单甲基奥里斯塔丁E (MMAE).
主要方法:
- 开发SGN-B6A,一种具有针对ITGB6和MMAE有效载荷特异性抗体的ADC.
- 在非小细胞肺癌,胰腺癌,喉癌和膀癌的临床前模型中进行体内测试.
- 在Cynomolgus子中进行非临床毒理学研究.
主要成果:
- 在各种固体瘤模型中,SGN-B6A在体内表现出活性,ITGB6表达水平不同.
- 毒理学研究显示可控的血液毒性,典型的MMAEADCs,没有显著的目标中介毒性.
- 在子中,每周高达5毫克/公斤或每3周高达6毫克/公斤的剂量被耐受.
结论:
- SGN-B6A是一种有前途的针对ITGB6的ADC,具有证明的临床前疗效和可管理的安全性.
- 一个I期临床试验 (NCT04389632) 正在进行中,以评估SGN-B6A在ITGB6表达型固体瘤患者中.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Activation of Integrins
3.5K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.5K
Tumor Immunotherapy
556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556
Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K
Integrins
4.0K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


